Sapu Nano is a clinical-stage biotechnology company developing Deciparticle (TM) nanomedicine therapeutics designed to optimize the delivery of hydrophobic oncology agents and peptide-based ...

Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables broad and consistent formulation of structurally diverse ...

Here, conceptual similarities between Mikhail Blagosklonny's hyperfunction theory of aging and Vladimir Dilman's elevation ...

A research team led by Park Hyun-woo, a biochemistry professor at Yonsei University, has introduced a pioneering method in ...

A landmark review published today in Genomic Psychiatry challenges researchers to fundamentally reconsider how the field ...

Detailed price information for Kazia Therapeutics Ltd ADR (KZIA-Q) from The Globe and Mail including charting and trades.

Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform ...

Tumour growth is reduced by exercise due to a shift in the body’s metabolism that means muscle cells outcompete cancer cells ...

In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur ...

It's well known that exercise is good for health and helps to prevent serious diseases, like cancer and heart disease, along ...

December 1, 2025Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAPBiodexa ...